ArticleJournal of medical case reports2026
A report of novel inactivating missense mutations of BRCA1 detected in patients with acute myeloid leukemia.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionExon 11 and exon 14 of BRCA1, a tumor suppressor gene, are known to be mutated in various cancers. METHODOLOGY: We screened 24 samples (13 from patients with acute myeloid leukemia and 11 from normal controls) using polymerase chain reaction to detect BRCA1 exon 11 and exon 14 mutations, if any. Purified polymerase chain reaction-amplified products of four samples (cases 1-4) were subjected to bidirectional sequence analysis.
resultsThe sequence analysis revealed in total 20 mutations. One novel frameshift mutation, that is, c.2339insG (p.E781fs), observed in case 1 promoted the synthesis of truncated protein (protein 1). In case 2, five novel insertions mutations c.2376insC (p.K793fs), c.2380insT (p.A794fs), c.2443insT (p.I815fs), c.2533insG (p.I845fs), and c.2511insG (p.N838fs), two novel deletion mutations, c.3762delG (p.N1255fs) and c.3830delC (p.A1277fs), along with one reported mutation,c.3621delG (p.Lys1208fs), were observed which resulted in a truncated protein (protein 2). Besides these, one nonsense c.2383A > T (p.K795X), and four missense c.2429A > C (p.N810T), c.2430C > A (p.N810K), c.3644A > T (p.N1215I), and c.3740 T > A (p.V1247D) were also observed in case 2. In case 3, a single missense c.3577 T > C (p.F1193L) and three silent mutations c.3576 T > C (p.P1192P), c.3579C > T (p.F1193F), and c.4311 T > C (p.S1437S) were noted, having no impact on the encoded protein's function. However, a unique silent mutation c.4252 T > C (p.L1418L) observed in case 4 did not influence the protein sequence. Bioinformatics analysis revealed that both truncated proteins (protein 1 and 2) have higher pI and considerably lower molecular weight than the wild-type BRCA1 protein. The molecular weight of protein 3 having one alteration (phenylalanine to leucine) varied slightly, and there was no difference in the characteristics of wild-type BRCA1 and protein 4.
conclusionThis study reveals the mutational spectrum of BRCA1 in patients with acute myeloid leukemia, representing unique missense and novel pathogenic mutations that can be further targeted for designing diagnostic and therapeutic strategies for acute myeloid leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.